Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

coiler123 Aug. 5 at 7:00 PM

$SLS Always here to protect my followers. Upon p3 release of the data the stock will either gain anywhere from 30 to 60% or LOOSE 70 to 80%. That is the standard. I consider this HIGH RISK. Diversify what you own.

1 · Reply

kwhistler Aug. 5 at 6:59 PM

$SLS Power Hour 💪

0 · Reply

Johnmtnb2018 Aug. 5 at 6:59 PM

$SLS Smith, Angelos said gps patients cured !

0 · Reply

OnTheBalance Aug. 5 at 6:55 PM

$SLS The Announcement will come when the company is ready. But imagine if there was an appetizer included ….✅referencing 42 living and unrelapsed GPS arm patients

0 · Reply

Jacob_Berkstein Aug. 5 at 6:54 PM

$SLS I wont forgive this time...

0 · Reply

Jacob_Berkstein Aug. 5 at 6:54 PM

$SLS They tried to silence me. They dont know what is coming for them...

1 · Reply

don23jon18 Aug. 5 at 6:53 PM

$SLS

0 · Reply

TheStormIsComing Aug. 5 at 6:52 PM

$SLS i think the reason this is taking so long is because they are getting the BO paperwork in order. it takes a bit.

1 · Reply

tommy45 Aug. 5 at 6:52 PM

$SLS spike over 12 before close coming guys just too much money buying this stock gl

0 · Reply

artynonymous Aug. 5 at 6:51 PM

$SLS Are people under the impression there are only two patients left in the entire trial? At least be familiar with the basic structure of the trial before saying silly stuff like this

2 · Reply

Sellas Life Sciences rises 11.0%

2026-07-17T14:05:57.000Z - 19 days ago

Sellas Life Sciences rises 10.2%

2026-07-06T11:05:22.000Z - 4 weeks ago

Sellas Life Sciences price target raised to $25 from $10 at Alliance Global

2026-07-01T14:05:22.000Z - 5 weeks ago

Sellas Life Sciences falls -11.0%

2026-06-30T14:05:32.000Z - 5 weeks ago

Sellas Life Sciences falls -8.9%

2026-06-29T14:05:39.000Z - 5 weeks ago

Sellas Life Sciences rises 16.8%

Jun 26, 2026, 12:30 PM EDT - 5 weeks ago

What's driving SLS stock higher today and what comes next?

Jun 16, 2026, 8:30 AM EDT - 7 weeks ago

SELLAS Life Sciences Group Transcript: AGM 2026

May 27, 2026, 9:00 AM EDT - 2 months ago

SELLAS Life Sciences Group Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026, 11:00 AM EDT - 2 months ago

SELLAS Life Sciences Group Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 19, 2026, 2:00 PM EDT - 2 months ago

SELLAS Life Sciences Group Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 14, 2026, 8:00 AM EDT - 2 months ago

SELLAS Life Sciences to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 3 months ago

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Earnings release: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

SELLAS Life Sciences Group Proxy statement: Proxy filing

Mar 27, 2026, 8:05 AM EDT - 4 months ago

These 16 stocks are a short seller's dream — likely losers no matter what the market does

EVCM LCID NNE SERV

2026-03-20T21:05:42.000Z - 4 months ago

Sellas Life Sciences files automatic mixed securities shelf

2026-03-20T11:11:35.000Z - 4 months ago

Sellas Life Sciences price target raised to $10 from $7.50 at Alliance Global

Mar 19, 2026, 4:05 PM EDT - 4 months ago

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 19, 2026, 4:00 PM EDT - 4 months ago

SELLAS Life Sciences Group Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 4 months ago

SELLAS Life Sciences Group Annual report: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 5 months ago

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

Mar 12, 2026, 8:35 AM EDT - 5 months ago

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Jan 14, 2026, 8:30 AM EST - 7 months ago

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Dec 29, 2025, 8:35 AM EST - 7 months ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 8 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

SELLAS Life Sciences Group Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 9 months ago

SELLAS Life Sciences Group Quarterly report: Q3 2025

Oct 29, 2025, 10:00 AM EDT - 10 months ago

SELLAS Life Sciences Group Transcript: R&D Day 2025

Oct 27, 2025, 8:30 AM EDT - 10 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Oct 10, 2025, 8:00 AM EDT - 10 months ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 10, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Jun 5, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q1 2025

Apr 28, 2025, 8:45 AM EDT - 1 year ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 1 year ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 8, 2025, 8:45 AM EDT - 1 year ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 20, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Annual report: Q4 2024

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Transcript: Study Update

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Press release: Study Update

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

SELLAS Life Sciences Group Earnings release: Q3 2024

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 2 years ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 2 years ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q1 2024

May 1, 2024, 8:35 AM EDT - 2 years ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Proxy statement: Proxy Filing

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 28, 2024, 8:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Registration statement: Registration Filing

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Transcript: Study Update

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Press release: Study Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

coiler123 Aug. 5 at 7:00 PM

1 · Reply

kwhistler Aug. 5 at 6:59 PM

$SLS Power Hour 💪

0 · Reply

Johnmtnb2018 Aug. 5 at 6:59 PM

$SLS Smith, Angelos said gps patients cured !

0 · Reply

OnTheBalance Aug. 5 at 6:55 PM

$SLS The Announcement will come when the company is ready. But imagine if there was an appetizer included ….✅referencing 42 living and unrelapsed GPS arm patients

0 · Reply

Jacob_Berkstein Aug. 5 at 6:54 PM

$SLS I wont forgive this time...

0 · Reply

Jacob_Berkstein Aug. 5 at 6:54 PM

$SLS They tried to silence me. They dont know what is coming for them...

1 · Reply

don23jon18 Aug. 5 at 6:53 PM

$SLS

0 · Reply

TheStormIsComing Aug. 5 at 6:52 PM

$SLS i think the reason this is taking so long is because they are getting the BO paperwork in order. it takes a bit.

1 · Reply

tommy45 Aug. 5 at 6:52 PM

$SLS spike over 12 before close coming guys just too much money buying this stock gl

0 · Reply

artynonymous Aug. 5 at 6:51 PM

$SLS Are people under the impression there are only two patients left in the entire trial? At least be familiar with the basic structure of the trial before saying silly stuff like this

2 · Reply

Odin000 Aug. 5 at 6:51 PM

$SLS

0 · Reply

FUD_Slayer Aug. 5 at 6:51 PM

$SLS Friendly reminder, you show up here and say nothing statements every once in a while but you seem to have a poor track record. If you wanna talk about GPs and BAT why don’t we talk about their safety profiles? Or BAT mOS?

1 · Reply

topstockalerts Aug. 5 at 6:50 PM

$SLS swing idea 💡

0 · Reply

Ricko4 Aug. 5 at 6:50 PM

$SLS doing great considering the number of short attacks we absorbed today

0 · Reply

dartgator Aug. 5 at 6:49 PM

$SLS “Patience is a virtue”! When is the T1?!?!

0 · Reply

Jawdat1959 Aug. 5 at 6:48 PM

$SLS 🚀🚀🚀

0 · Reply

SellasgpsCurativeBAT11 Aug. 5 at 6:48 PM

$SLS Dr. Angelos Stergiou agrees with my Analysis as a Biostatistician: “GPS induces a specific T-cell response in nearly all patients. Data suggests that patients who mount a strong immune response may achieve significantly prolonged remission, effectively keeping the leukemia "dormant" via immune surveillance.” “We are moving toward a world where we can hopefully treat the fundamental biology of AML. Our mission is to move past "managing" the disease and toward potentially establishing curative outcomes as the standard of care-preserving the "building" while eliminating the threat for good.” 👇 ✌️🙏❤️‍🩹

0 · Reply

TheFrogPrince Aug. 5 at 6:47 PM

$SLS 📈 but green ✅

1 · Reply

coiler123 Aug. 5 at 6:47 PM

$SLS Freindly reminder for those that are posting this company will lead you to the promised land with significant profits. It not known which arm of the trial—the galinpepimut-S (GPS) group or the Best Available Therapy (BAT) control group—the 79th and 80th patient events belong to.

5 · Reply

Chessdoc Aug. 5 at 6:46 PM

$SLS I think the point that bikechain is making is extremely important and perhaps overlooked by many traders/investors here: This will not just make medical headlines, but general media headlines: a cure (albeit functional) without side effects!! Many generations have lived with the fear of cancer, and perhaps more so of the treatment side effects!! I would estimate that the majority of people here over 40 years old know someone who has developed cancer, and perhaps even refused treatment due to such fears!? I know I have.

2 · Reply

Nelvestor Aug. 5 at 6:43 PM

$SLS me when the 80th hits

1 · Reply

408stockbroker Aug. 5 at 6:43 PM

$SLS I'm in the waiting room, knowing my fortune is about to be delivered... I know it's coming, but the wait feels like forever.

0 · Reply

Market Cap	2.21B
Revenue (ttm)	0.00
Net Income (ttm)	-26.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,896,683
Avg Vol	9,326,094
Day's Range	N/A - N/A
Shares Out	196.63M
Stochastic %K	70%
Beta	2.48
Analysts	Strong Sell
Price Target	$27.50